BCL2L1 and colorectal carcinoma: Rego exhibited a weaker efficiency on Bcl-xl, Noch1, Bmi-1 than CADPE and decreased VEGF in some CRC cell lines with no obvious effect on the CD133 levels in all tested cell lines (Fig. 3f).